Urinary bladder hyperplasia in the rat: non-specific pathogenetic considerations using a beta-lactam antibiotic

Area of Science:

• Toxicology
• Urothelial Biology
• Carcinogenesis

Background:

• Neoplasia in humans is linked to chemical exposure targeting the urinary bladder urothelium.
• Preneoplastic changes, particularly hyperplasia, are observed in animal models following chemical exposure.
• Distinguishing between adaptive, reparative, and preneoplastic hyperplasia is crucial for toxicity studies.

Purpose of the Study:

• To investigate the effects of the synthetic beta-lactam penem antibiotic FCE 22891 and its metabolite FCE 22101 on the urinary bladder urothelium.
• To elucidate the mechanism behind adaptive urothelial hyperplasia observed in rats.
• To emphasize the importance of differentiating hyperplasia types in preclinical toxicity assessments.

Main Methods:

• Histopathological examination of urinary bladder urothelium in various animal species following exposure to FCE 22891 and FCE 22101.
• Pharmacokinetic analysis of FCE 22891 and FCE 22101.
• Comparative analysis of hyperplasia progression with dose and time, and reversibility.

Main Results:

• FCE 22891 and FCE 22101 induced adaptive urothelial hyperplasia exclusively in rats.
• This adaptive hyperplasia was dose- and time-independent and reversible.
• Pharmacokinetic data suggested reduced intravesicular urine pH as the cause of adaptive hyperplasia in rats, with no relevance to human therapeutic use.

Conclusions:

• Adaptive urothelial hyperplasia induced by FCE 22891/FCE 22101 in rats is a non-progressive, reversible phenomenon.
• The mechanism involves a reduction in intravesicular urine pH, unrelated to therapeutic efficacy.
• Accurate differentiation of adaptive, reparative, and preneoplastic hyperplasia is essential for reliable preclinical toxicity studies.